Market Access Today’s Post

How to keep GPs informed out about new medications? With the TGA approving many new prescription medicines in 2024, pharma companies have the challenge as to how best update doctors on all these changes so that they can prescribe the most effective treatments based on the latest drug advancements. adg's Inside Healthcare looks back through the archives to share learning’s on this highly relevant topic. #PharmaGTM #PharmaMarketing

Choosing the right partner makes all the difference.

This strategic partnership between Community Health Systems and Cost Plus Drugs represents an innovative approach to addressing rising pharmaceutical costs and drug shortages. This collaboration feels like a real game-changer for making crucial medications more affordable and accessible for patients. This partnership also represents a promising step towards addressing major issues impacting healthcare affordability and accessibility. Innovative collaborations like this have the potential to positively transform the pharmaceutical supply chain for both healthcare providers and patients.

🚨 Breaking News: G-BA Ends Data Collection Requirement for Marstacimab! 🚨 In a significant move, Berlin's Federal Joint Committee (G-BA) has officially halted the mandate for application-related data collection on Marstacimab, following its approval as an orphan drug. This decision underscores the stringent criteria surrounding data collection mandates and highlights how orphan drug classification can streamline regulatory processes. Key Highlights: ✅ Marstacimab approved for routine prophylaxis in patients aged 12+ with severe hemophilia A or B. ✅ G-BA's decision reflects a broader trend in pharmaceutical strategies to optimize market access. ✅ Patients can now expect quicker access to essential treatments, enhancing health outcomes. This development not only benefits pharmaceutical companies but also paves the way for improved patient care. For more insights on this pivotal decision and its implications, click on the link! #G-BA #HealthcareInnovation #Marstacimab #OrphanDrug #Pharma #PharmaceuticalNews #RegulatoryAgencies #RegulatoryUpdates #MarketAccess #MarketAccessToday

The next round of #InflationReductionAct Medicare Drug Price Negotiations is coming soon, with the next 15 #drug brands to be announced by Feb. 1st. As the piece below states, the selection process is rigorous. What they don't say is that the process that the selected companies have to go through is also quite rigorous. It is a process like no other, that requires fine-tuned coordination of a cross-functional team, and a clear roadmap for each step of the way. If you are one of those companies, are you ready? https://lnkd.in/eXpd3QG9 #IRA #Medicare #DrugPriceNegotiation

Prescription medication costs are on the rise, disproportionately affecting communities of color. Recent findings from Patients For Affordable Drugs, reveals that Black and Latino seniors struggle more to afford their medicine, while pharmaceutical companies continuously increase prices for drugs like Enhertu and Revlimid. No one should have to make the difficult choice between essential medications and basic needs. It's time for policy action to counter the greed of Big Pharma and promote health equity. https://lnkd.in/gRjrEV85 #AffordablePrescriptions #AffordableDrugsNow #BigPharma #EndBigPharmaGreed #HealthEquity #OCAP

An interesting read about the recent Senate H.E.L.P. Committee hearing on prescription drugs costs. Pharmaceuticals represent only ~14% of US healthcare spend, but often take on an inordinate share of blame for the problem of healthcare affordability and suboptimal outcomes in the US. The problems of the US healthcare system are multifactorial- rooted in the fee-for-service model and the complex web of healthcare delivery, payers, PBMs, pharmaceutical and medical device companies. The author asserts that changes in one part of the healthcare ecosystem will have significant impacts on other components, the total cost of care, and overall health outcomes, so there is no easy solution. https://lnkd.in/ezZwBb3J

PBMs in the Pharmaceutical Industry are under scrutiny for perceived lack of transparency, misaligned incentives, and failure to demonstrate value. The intricate roles of key players hold stakes in the game. Discover how to achieve full accountability. #PharmaceuticalIndustry #Healthcare #HealthcareInnovation

Medicine Just Got a Digital Upgrade with Software-Enhanced Drugs™. Yesterday, at The Frontiers Health conference, Click Founder and CEO David Benshoof Klein delivered his keynote, speaking to a future where software-enhanced drug™ therapies will be standard of care. Software-enhanced drug therapies are drug-software combination products that target the unique needs of a medication and patient population to deliver added clinically meaningful benefit. The value of these therapies is reinforced by FDA's Prescription Drug Use Related Software (PDURS) Draft Guidance, which outlines how the FDA intends to apply its drug labeling authorities to software outputs associated with prescription drugs. The guidance covers a full spectrum of use cases, but importantly specifies that when software used with a drug demonstrates added clinically meaningful benefit compared to drug alone in one or more adequate and well-controlled trials, that added clinical benefit can be included in the drug label, right in the package insert. These will soon be routinely developed and launched for leading pharmaceutical brands as “SE” (software-enhanced) dosage forms, e.g., “*Drug Name*™ SE™”. Software-enhanced drug products are thus a high-value, high-rigor category of product within PDURS. Compared to other PDURS solutions, these treatments are differentiated by a high level of clinical validation, development in compliance with software-as-a-medical device requirements for cybersecurity and quality, and offer patients an engaging and personalized treatment experience to achieve superior clinical outcomes. To learn more, visit us next week at HLTH (Booth #2137) or reach out to bd@clicktherapeutics.com #FrontiersHealth #FH24 #FrontiersHealth24 #PDURS #PrescriptionDigitalTherapeutics #DrugDevelopment #SoftwareEnhancedDrugs

Check out last week's top stories from Market Access Today! #marketaccess #reimbursement #pricing